A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

NCT06699121 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

87

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Sclerosing Cholangitis (PSC)

Interventions

DRUG: LB-P8 low-dose
DRUG: LB-P8 high-dose
DRUG: Placebo

Sponsor

LISCure Biosciences